We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Alkermes PLC is a fully integrated global biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in major therapeutic areas. The company utilizes several collaborative arrangements to develop an... Alkermes PLC is a fully integrated global biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in major therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, to access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. Show more
Alkermes to Present Positive Clinical Data From Phase 1b Study of ALKS 2680 in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia at Sleep Europe 2024 PR Newswire DUBLIN, Sept. 23, 2024...
Alkermes to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Conference PR Newswire DUBLIN, Sept. 19, 2024 DUBLIN, Sept. 19, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq:...
Alkermes Announces Launch of 7th Annual Alkermes Pathways Research Awardsยฎ Program PR Newswire DUBLIN, Sept. 13, 2024 โย Competitive Grant Program to Offer Individual Grants of Up to $100,000 per...
Alkermes to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference PR Newswire DUBLIN, Aug. 28, 2024 DUBLIN, Aug. 28, 2024ย /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS...
Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2 PR Newswire DUBLIN, Aug. 22, 2024 DUBLIN, Aug. 22, 2024 /PRNewswire/...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.32 | 1.15190784737 | 27.78 | 29.02 | 27.4 | 2415483 | 28.25904009 | CS |
4 | -0.02 | -0.0711237553343 | 28.12 | 29.02 | 25.645 | 1632591 | 27.75422956 | CS |
12 | 4.04 | 16.791354946 | 24.06 | 29.02 | 22.9 | 1767372 | 26.5786906 | CS |
26 | 0.73 | 2.66715381805 | 27.37 | 29.02 | 22.9 | 1788946 | 25.55727964 | CS |
52 | -0.89 | -3.07002414626 | 28.99 | 32.88 | 22.01 | 2030104 | 26.46892992 | CS |
156 | -2.84 | -9.17905623788 | 30.94 | 33.71 | 21.24 | 1636064 | 26.84714859 | CS |
260 | 7.05 | 33.4916864608 | 21.05 | 33.71 | 11.98 | 1591573 | 24.27068684 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions